Lifelong Oral Nicotine Slows Motor Aging by Rewiring Sphingolipid Metabolism in Mice
A 22-month mouse study finds oral nicotine preserves motor function and reprograms aging metabolism via sphingolipid and NAD⁺ pathways.
Summary
Chinese researchers gave mice oral nicotine for 22 months and found it significantly slowed age-related motor decline without causing organ toxicity or immune dysfunction. Using multi-organ metabolomics and gut microbiome profiling, they traced the benefit to nicotine's ability to rebalance sphingolipid metabolism — specifically reducing ceramide buildup and boosting NAD⁺ availability in muscle tissue. A novel Behavior-Metabolome Age (BMAge) score confirmed that nicotine-treated mice were biologically younger than controls. The findings suggest that isolated nicotine, at low oral doses, may have anti-aging properties distinct from the harms of tobacco smoke, pointing to sphingolipid homeostasis as a druggable target for sarcopenia and motor decline.
Detailed Summary
Age-related motor decline and sarcopenia represent major threats to healthspan, yet the metabolic mechanisms driving them remain incompletely understood. This study from the Shenzhen Institutes of Advanced Technology (Chinese Academy of Sciences) investigated whether lifelong low-dose oral nicotine could attenuate aging-associated motor dysfunction and, if so, through what systemic metabolic mechanisms. The research is notable for its longitudinal scope — 22 months of continuous nicotine exposure — and its integration of behavioral, metabolomic, microbiome, and cellular data into a unified mechanistic framework.
Mice were permitted to voluntarily consume nicotine in drinking water over a 22-month period, spanning from young adulthood through old age (24 months total). Comprehensive motor function assessments were conducted at multiple time points. At 24 months, nicotine-treated mice showed significantly attenuated motor decline compared to controls, with no evidence of pathological changes in major peripheral organs (liver, kidney, heart) and no signs of immune system dysfunction. This safety profile is critical, as it suggests the effects observed are attributable to nicotine's pharmacological activity rather than systemic toxicity.
To understand the metabolic basis of these effects, the researchers performed multi-organ metabolomic profiling across brain, muscle, liver, and gut tissues. Network analysis identified nicotine-responsive pathways centered on glycolipid metabolism and energy homeostasis. Longitudinal gut microbiota profiling using Series Expression Miner (SEM)-based analysis revealed that nicotine consumption preserved microbiota composition over time and specifically altered microbial-derived metabolites linked to the sphingolipid pathway. The sphingolipid pathway is known to regulate age-related muscle dysfunction and sarcopenia, making this a mechanistically coherent finding.
Focused assays in aged mice and C2C12 myoblast cells confirmed that nicotine regulates sphingolipid turnover by modulating sphingomyelin synthases and neutral sphingomyelinases. This enzymatic regulation reduced ceramide accumulation — a lipid species strongly associated with muscle atrophy and mitochondrial dysfunction in aging — while simultaneously enhancing NAD⁺ bioavailability and improving energy metabolism in muscle tissue. The ceramide-to-sphingomyelin balance emerged as a key metabolic node linking nicotine exposure to functional motor outcomes.
To quantify the overall biological aging impact, the authors developed a novel composite metric called the Behavior-Metabolome Age (BMAge) score, integrating behavioral performance with metabolomic signatures. Nicotine-treated mice scored significantly lower on BMAge — indicating a biologically younger phenotype — compared to age-matched controls. This multi-dimensional aging clock approach adds rigor beyond single-endpoint assessments. The authors acknowledge that these findings are in mice and that the oral nicotine doses used are substantially lower than those encountered through smoking, meaning translation to humans requires careful dose-finding and long-term safety studies.
Key Findings
- Oral nicotine over 22 months significantly attenuated age-related motor decline in mice at 24 months of age, with no pathological changes detected in liver, kidney, or heart tissue
- Multi-organ metabolomic profiling identified nicotine-responsive remodeling of glycolipid metabolism and energy homeostasis across brain, muscle, liver, and gut
- Longitudinal gut microbiota analysis (SEM-based) showed nicotine preserved microbiota composition and altered microbial-derived sphingolipid metabolites associated with sarcopenia
- Nicotine regulated sphingomyelin synthases and neutral sphingomyelinases in aged muscle tissue and C2C12 cells, reducing ceramide accumulation — a driver of muscle atrophy
- Sphingolipid rebalancing was accompanied by enhanced NAD⁺ bioavailability and improved mitochondrial energy metabolism in muscle
- A novel Behavior-Metabolome Age (BMAge) score confirmed nicotine-treated mice exhibited a biologically younger phenotype than age-matched controls
- No immune system dysfunction was observed in nicotine-treated mice, supporting a favorable safety profile at the doses studied
Methodology
Male mice received voluntary oral nicotine in drinking water for 22 months (assessed at 24 months of age), with age-matched water controls. Motor function was assessed longitudinally using standard behavioral assays. Multi-organ metabolomics was performed at endpoint across brain, muscle, liver, and gut; gut microbiota was profiled longitudinally using 16S sequencing analyzed with Series Expression Miner (SEM). Mechanistic validation was conducted in C2C12 myoblast cells with sphingolipid enzyme assays and NAD⁺ quantification. The BMAge score was constructed by integrating behavioral and metabolomic data using machine learning approaches.
Study Limitations
This study was conducted entirely in mice, and the oral nicotine doses used are substantially lower than human smoking exposure, limiting direct clinical translation. The study does not report specific effect sizes or p-values for all behavioral outcomes in the published abstract, and long-term human safety data for chronic low-dose nicotine are lacking. The authors do not report conflicts of interest related to tobacco or nicotine industry funding, but the study's framing of nicotine as potentially beneficial warrants independent replication.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.